Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Grazoprevir

FDA-approved product (tablet, oral).

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Grazoprevir
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Chronic hepatitis C virus infection

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Antivirals for treatment of hcv infections
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AP11

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA, E. coli and K. pneumoniae. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA61.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli46.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae44.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis57.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Grazoprevir in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Grazoprevir with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Administration of Zepatier (Grazoprevir Plus Elbasvir) in Chronic Hemodialysis (HD) Patients With Hepatitis C

    NCT03365635 · start 2019-09-22

    Registered record
    Registry ID
    NCT03365635
    Conditions
    Hepatitis C; Hemodialysis; Nosocomial Infection
    Interventions
    Elbasvir 50 MG / Grazoprevir 100 MG [Zepatier]
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2019-09-22
    Completion
    2020-09-01
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C; Hemodialysis; Nosocomial Infection
    InterventionElbasvir 50 MG / Grazoprevir 100 MG [Zepatier]
    PhasePhase 4
    Registry statusCompleted

  • HepATocellular Cancer Hcv Therapy Study

    NCT04546802 · start 2019-09

    Registered record
    Registry ID
    NCT04546802
    Conditions
    Hepatocellular Carcinoma; Hepatoma; Liver Cell Carcinoma; Hepatitis C
    Interventions
    Elbasvir / Grazoprevir Oral Tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2019-09
    Completion
    2023-06
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatocellular Carcinoma; Hepatoma; Liver Cell Carcinoma; Hepatitis C
    InterventionElbasvir / Grazoprevir Oral Tablet
    PhasePhase 3
    Registry statusWithdrawn

  • Real-world Effectiveness and Safety of Treatment With DAAs in Patients With CHC(Chronic Hepatitis C)

    NCT03887637 · start 2019-03-30

    Registered record
    Registry ID
    NCT03887637
    Conditions
    Chronic Hepatitis C
    Interventions
    DAAs
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2019-03-30
    Completion
    2019-09-30
    Enrolment
    180

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hepatitis C
    InterventionDAAs
    PhaseNot recorded
    Registry statusUnknown

  • ATTIC - Access To Treat in the Community

    NCT03797066 · start 2019-03-23

    Registered record
    Registry ID
    NCT03797066
    Conditions
    Hepatitis C, Chronic
    Interventions
    ZEPATIER 50Mg-100Mg Tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2019-03-23
    Completion
    2020-11-30
    Enrolment
    13

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C, Chronic
    InterventionZEPATIER 50Mg-100Mg Tablet
    PhasePhase 4
    Registry statusTerminated

  • Grazoprevir/Elbasvir for Genotype 1b Chronic Hepatitis C After Liver or Kidney Transplantation

    NCT03723824 · start 2019-02-14

    Registered record
    Registry ID
    NCT03723824
    Conditions
    Chronic Hepatitis c; Liver Transplant Infection; Kidney Transplant Infection
    Interventions
    grazoprevir 100 mg/ elbasvir 50 mg, Zepatier®
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2019-02-14
    Completion
    2021-03-13
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hepatitis c; Liver Transplant Infection; Kidney Transplant Infection
    Interventiongrazoprevir 100 mg/ elbasvir 50 mg, Zepatier®
    PhasePhase 4
    Registry statusTerminated

  • Drug-Drug Interactions of Grazoprevir/Elbasvir in Taiwan

    NCT03706222 · start 2018-10-22

    Registered record
    Registry ID
    NCT03706222
    Conditions
    Drug Interaction Potentiation
    Interventions
    elbasvir/grazoprevir
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2018-10-22
    Completion
    2019-02-25
    Enrolment
    400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDrug Interaction Potentiation
    Interventionelbasvir/grazoprevir
    PhaseNot recorded
    Registry statusCompleted

  • Safety and Efficacy of Grazoprevir and Elbasvir for GT1ang GT6 With and Without HIV

    NCT03037151 · start 2018-08-01

    Registered record
    Registry ID
    NCT03037151
    Conditions
    Compensated Cirrhosis
    Interventions
    Grazaoprevir/Elbasavir; Grazaoprevir/Elbasavir/RBV
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2018-08-01
    Completion
    2020-12-31
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCompensated Cirrhosis
    InterventionGrazaoprevir/Elbasavir; Grazaoprevir/Elbasavir/RBV
    PhasePhase 4
    Registry statusUnknown

  • A Single-arm Evaluation of the Effect of HCV Treatment on Cardiovascular Disease Risk

    NCT03585101 · start 2018-08

    Registered record
    Registry ID
    NCT03585101
    Conditions
    Hepatitis C
    Interventions
    Elbasvir/grazoprevir
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2018-08
    Completion
    2020-04
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C
    InterventionElbasvir/grazoprevir
    PhasePhase 4
    Registry statusWithdrawn

  • Eight Weeks of Elbasvir/Grazoprevir in the Treatment of HCV Genotype 4

    NCT03578640 · start 2018-07-01

    Registered record
    Registry ID
    NCT03578640
    Conditions
    Hepatitis C, Chronic
    Interventions
    Elbasvir, Grazoprevir 50-100Mg Oral Tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2018-07-01
    Completion
    2020-06-30
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C, Chronic
    InterventionElbasvir, Grazoprevir 50-100Mg Oral Tablet
    PhasePhase 3
    Registry statusCompleted

  • EBR/GZR for HCV-1b Patients Receiving Hemodialysis

    NCT03420300 · start 2018-06-05

    Registered record
    Registry ID
    NCT03420300
    Conditions
    Hepatitis C
    Interventions
    EBR/GZR
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2018-06-05
    Completion
    2020-02-03
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C
    InterventionEBR/GZR
    PhasePhase 4
    Registry statusCompleted

  • Hepatitis C (HCV) Cure and Kidney Health

    NCT03407703 · start 2018-03-27

    Registered record
    Registry ID
    NCT03407703
    Conditions
    Hepatitis C
    Interventions
    Elbasvir / Grazoprevir Oral Tablet [Zepatier]
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2018-03-27
    Completion
    2019-12-31
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C
    InterventionElbasvir / Grazoprevir Oral Tablet [Zepatier]
    PhaseNot recorded
    Registry statusUnknown

  • Efficacy and Safety of Elbasvir/Grazoprevir in Brazilian Participants With Chronic Hepatitis C Virus (HCV) Genotype 1 Infection With Advanced Fibrosis (F3 and F4)

    NCT03143998 · start 2018-02-12

    Registered record
    Registry ID
    NCT03143998
    Conditions
    Hepatitis C
    Interventions
    MK-5172A
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2018-02-12
    Completion
    2019-01-12
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C
    InterventionMK-5172A
    PhasePhase 4
    Registry statusWithdrawn

  • Elbasvir (EBR)/Grazoprevir (GZR) in Pediatric Participants With Chronic Hepatitis C Infection (MK-5172-079)

    NCT03379506 · start 2018-01-25

    Registered record
    Registry ID
    NCT03379506
    Conditions
    HCV Infection
    Interventions
    EBR/GZR FDC Tablet; Placebo; Grazoprevir Oral Granules; Elbasvir Oral Granules
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2018-01-25
    Completion
    2020-07-23
    Enrolment
    57

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHCV Infection
    InterventionEBR/GZR FDC Tablet; Placebo; Grazoprevir Oral Granules; Elbasvir Oral Granules
    PhasePhase 2
    Registry statusCompleted

  • A Direct obserVed therApy vs fortNightly CollEction Study for HCV Treatment - ADVANCE HCV Study

    NCT03236506 · start 2018-01-19

    Registered record
    Registry ID
    NCT03236506
    Conditions
    Hepatitis C
    Interventions
    Elbasvir/Grazoprevir 50 MG-100 MG Oral Tablet; Psychological intervention; Sofosbuvir 400 MG
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2018-01-19
    Completion
    2020-10-28
    Enrolment
    129

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C
    InterventionElbasvir/Grazoprevir 50 MG-100 MG Oral Tablet; Psychological intervention; Sofosbuvir 400 MG
    PhasePhase 2
    Registry statusCompleted

  • Smartphone Based aDOT Treatment With Fixed-Dose Elbasvir and Grazoprevir in PWIDs

    NCT03127358 · start 2017-11-14

    Registered record
    Registry ID
    NCT03127358
    Conditions
    Hepatitis C; Medication Adherence
    Interventions
    AiCure; AiCure with gamification
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2017-11-14
    Completion
    2019-02-06
    Enrolment
    11

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C; Medication Adherence
    InterventionAiCure; AiCure with gamification
    PhaseNot applicable
    Registry statusCompleted